Oxoid expands in Australia
diagnostics assets of microbiology specialist Medvet Science of
Australia.
UK-based microbiology firm Oxoid has reached agreement to acquire the prepared media and diagnostics assets of Medvet Science of Australia, a supplier of microbiology products and testing services to the healthcare and food industries.
From early September, Oxoid will take direct control of the Medvet manufacturing operations in Adelaide - a purpose-built facility created less than three years ago. A total of 26 staff will transfer and become Oxoid employees.
"This acquisition brings together two like-minded companies," said Mike Smith, Oxoid's president. Medvet offers a range of products and services, including Hazard Analysis and Critical Control Points (HACCP) for manufacturing processes, drug screening and diagnostics. Under the terms of the deal, Oxoid will acquire the Australian firm's Microbact biochemical identification systems and Serobact rapid latex agglutination tests, which will be marketed worldwide under the Oxoid brand.
Wayne Chitty, CEO of Oxoid Australia, said: "we have worked closely with Medvet for many years. This acquisition demonstrates Oxoid's commitment to the Australasian and Asia Pacific markets and allows us to extend the range of products and services that we provide within these regions."
